PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 33 filers reported holding PDL BIOPHARMA INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $127,000 | -38.3% | 40,402 | -42.8% | 0.00% | -33.3% |
| Q2 2020 | $206,000 | -44.3% | 70,622 | -38.0% | 0.00% | +50.0% |
| Q4 2019 | $370,000 | -35.3% | 113,986 | -56.9% | 0.00% | -60.0% |
| Q3 2019 | $572,000 | +20.7% | 264,622 | +75.2% | 0.01% | 0.0% |
| Q2 2019 | $474,000 | -7.4% | 151,020 | +9.6% | 0.01% | 0.0% |
| Q1 2019 | $512,000 | +232.5% | 137,734 | +158.9% | 0.01% | +150.0% |
| Q4 2018 | $154,000 | -31.6% | 53,195 | -37.8% | 0.00% | -33.3% |
| Q3 2018 | $225,000 | -40.0% | 85,543 | -46.6% | 0.00% | -40.0% |
| Q2 2018 | $375,000 | +11.3% | 160,075 | +39.6% | 0.01% | 0.0% |
| Q1 2018 | $337,000 | +287.4% | 114,700 | +261.3% | 0.01% | +150.0% |
| Q4 2017 | $87,000 | +10.1% | 31,746 | +36.8% | 0.00% | 0.0% |
| Q3 2017 | $79,000 | -66.5% | 23,214 | -79.2% | 0.00% | -80.0% |
| Q4 2016 | $236,000 | +237.1% | 111,390 | +435.5% | 0.01% | +100.0% |
| Q3 2016 | $70,000 | -59.5% | 20,800 | -57.6% | 0.01% | -73.7% |
| Q4 2015 | $173,000 | – | 49,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Silver Point Capital L.P. | 23,783,273 | $58,745,000 | 6.82% |
| Park West Asset Management LLC | 14,397,212 | $35,561,000 | 0.74% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 633,700 | $1,565,000 | 0.24% |
| JBF Capital, Inc. | 543,990 | $1,344,000 | 0.22% |
| Context Capital Management, LLC | 465,172 | $1,149,000 | 0.16% |
| Bellecapital International Ltd. | 108,025 | $267,000 | 0.09% |
| FNY Investment Advisers, LLC | 100,000 | $247,000 | 0.07% |
| WINTON GROUP Ltd | 291,360 | $720,000 | 0.05% |
| Freedom Investment Management, Inc. | 54,735 | $135,000 | 0.02% |
| HANCOCK WHITNEY CORP | 187,757 | $464,000 | 0.02% |